RBC Capital on 89bio Inc. (ETNB) Following Phase II ENLIVEN data: 'The study looked successful across the board'
Tweet Send to a Friend
RBC Capital analyst Brian Abrahams reiterated an Outperform rating and $27.00 price target on 89bio Inc. (NASDAQ: ETNB).The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
